ArticlebioRxiv : the preprint server for biology2025
Antibody-Initiated Loop-Mediated Isothermal Nucleic Acid Amplification (ai-LAMP) as a New Biosensor for Antigen Detection.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Highly sensitive protein detection is critical in research and healthcare diagnostics but remains limited to resource intensive environments. In contrast, lateral flow immunoassay (LFIA)-based diagnostics are popular point-of-care tests due to their simplicity and user-friendly format but lack sensitivity for detecting the low concentrations of proteins that are present early in infections and among asymptomatic individuals. To overcome these limitations, we developed a novel biosensor platform utilizing antibody-initiated loop-mediated isothermal amplification (ai-LAMP) with an LFIA readout for protein detection. This platform integrates protein-specific antibody-antigen binding with the robust signal amplification of LAMP. By conjugating pairs of antibodies to overlapping DNA strands, the presence of a target protein brings the DNA strands into proximity, completing a DNA target to directly initiate the LAMP reaction without any additional ligation step. This approach facilitates the rapid detection of low concentration proteins with a clear visual readout and can be performed in 3 steps from sample to answer. Using ai-LAMP we detected HIV-1 p24 on commercially available LFIAs at a limit of detection (LOD) of 20 fM (0.53 pg/mL), demonstrating 46x improvement over existing HIV p24 LFIAs. The use of ai-LAMP eliminates the need for sophisticated laboratory equipment to detect protein targets in low concentrations, paving a new way for rapid and accessible biomarker detection in clinical and research settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.